Regulating antibiotics in an era of resistance: The historical basis and continued need for adequate and well-controlled investigations

Annals of Internal Medicine

Volumn 163, Issue 5, 2015, Pages 386-388

  Podolsky, Scott H ^a   Powers, John H ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; HISTORY; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

ANTI-BACTERIAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, BACTERIAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84940536674     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0802     Document Type: Article

References (15)

1. Dimasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69:297-307. [PMID: 11371997]
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272-7. [PMID: 20130567] doi: 10.1038/clpt.2009.295
3. Evans R, Hinds S, Hammock D. Portfolio analysis and R&D decision making. Nat Rev Drug Discov. 2009;8:189-90. [PMID: 19182818] doi: 10.1038/nrd2744
4. Doshi P. Speeding new antibiotics to market: a fake fix? BMJ. 2015;350:h1453. [PMID: 25814536] doi:10.1136/bmj.h1453
5. Podolsky SH. The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics. Baltimore: Johns Hopkins Univ Pr; 2015.
6. Finland M. The new antibiotic era: for better or for worse? Antibiotic Med Clin Ther (New York). 1957;4:17-20. [PMID: 13382110]
7. Lear J. Taking the miracle out of the miracle drugs. Saturday Review. 3 January 1959:35-41.
8. Upjohn v Finch, 422 F2d 944 (6th Cir 1970).
9. Carpenter DP. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton: Princeton Univ Pr; 2010.
10. U.S. Food and Drug Administration. Labeling for daptomycin (Cubicin). 2014. Accessed at www.accessdata.fda.gov/drugsatfda-docs/label/2014/021572s046lbl.pdf on 8 July 2015.
11. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. Silver Spring, MD: U.S. Food and Drug Administration; 2013. Accessed at www.fda.gov/Drugs/DrugSafety/ucm369580.htm on 8 July 2015.
12. U.S. Food and Drug Administration. Doribax (doripenem): Drug Safety Communication-Risk When Used to Treat Pneumonia on Ventilated Patients. Silver Spring, MD: U.S. Food and Drug Administration; 2014. Accessed at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm388328.htm on 8 July 2015.
13. U.S. Food and Drug Administration. FDA approves Vibativ for hospitalized patients with bacterial pneumonia [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 21 June 2013. Accessed at www.fda.gov/newsevents/newsroom/pressannouncements/ucm358209.htm on 8 July 2015.
14. U.S. Food and Drug Administration. FDA approves new antibacterial drug Avycaz [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 25 February 2015 [updated 26 February 2015]. Accessed at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm on 8 July 2015.
15. DeLauro R. DeLauro Introduces HEAL Act to Address Antibiotic-Resistant Superbugs [press release]. 2015. Accessed at http://delauro.house.gov/index.php?option=com-content&view=article&id=1822:delauro-introduces-heal-act-to-address-antibiotic-resistant-superbugs&catid=2&Itemid=21 on 8 July 2015.